When the Damage Is Done: Selecting Patients for Head and Neck Cancer Chemoprevention Trials.

about

When the Damage Is Done: Selecting Patients for Head and Neck Cancer Chemoprevention Trials.

Item

http://www.wikidata.org/entity/Q46096667

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

When the Damage Is Done: Selec ...... Cancer Chemoprevention Trials.

@en

When the Damage Is Done: Selec ...... Cancer Chemoprevention Trials.

@nl

type

Item

label

When the Damage Is Done: Selec ...... Cancer Chemoprevention Trials.

@en

When the Damage Is Done: Selec ...... Cancer Chemoprevention Trials.

@nl

prefLabel

When the Damage Is Done: Selec ...... Cancer Chemoprevention Trials.

@en

When the Damage Is Done: Selec ...... Cancer Chemoprevention Trials.

@nl

P1476

When the Damage Is Done: Selec ...... Cancer Chemoprevention Trials.

@en

P2093

Daniel E Johnson

http://www.w3.org/2001/XMLSchema#string

Julie E Bauman

http://www.w3.org/2001/XMLSchema#string

P2860

Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma

Mechanisms of Cancer Induction by Tobacco-Specific NNK and NNN.

Chemoprevention targets for tobacco-related head and neck cancer: past lessons and future directions.

Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.

Tobacco smoke biomarkers and cancer risk among male smokers in the Shanghai cohort study

Optimized Liquid Chromatography Nanoelectrospray-High-Resolution Tandem Mass Spectrometry Method for the Analysis of 4-Hydroxy-1-(3-pyridyl)-1-butanone-Releasing DNA Adducts in Human Oral Cells.

How much do smoking and alcohol consumption explain socioeconomic inequalities in head and neck cancer risk?

Oral Cancer Chemoprevention--The End of EPOC, the Beginning of an Epoch of Molecular Selection.

Metabolic activation of N-alkylnitrosamines in genetically engineered Salmonella typhimurium expressing CYP2E1 or CYP2A6 together with human NADPH-cytochrome P450 reductase.

P304

489-490

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1158/1940-6207.CAPR-17-0197

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28821544

http://www.w3.org/2001/XMLSchema#string

P932

5915371

http://www.w3.org/2001/XMLSchema#string